Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

AsthmaRespiratory Tract Infection

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register

Respir Med

Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C

doi: 10.1016/j.rmed.2025.108203

RECOMMENDED

Asthma

Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G

doi: 10.3390/jcm14062075

Asthma

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

Adv Ther

Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B

doi: 10.1007/s12325-025-03231-6

COMMENTED

Asthma

XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Chest

Pelaia G, Jackson DJ, Nair P, Emmanuel B, Tran TN, Menzies-Gow A, Watt M, Kayaniyil S, Boarino S, Nuevo J, Pardal M, Shavit A, Shih VH, Cohen D, Loureiro C, Padilla-Galo A

doi: 10.1016/j.chest.2025.04.011

RECOMMENDED

Asthma

Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Chiner E, Murcia M, Boira I, Bernabeu MÁ, Esteban V, Martínez-Moragón E

doi: 10.3390/jcm13144247

COMMENTED

Asthma

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

J Asthma Allergy

Mobayed H, Al-Nesf M, Ibrahim T, Aqel S, Al-Ahmad M, Bousquet J

doi: 10.2147/JAA.S517784

RECOMMENDED

Further Publications

Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Pediatr Pulmonol

Phipatanakul W, Vogelberg C, Bacharier LB, Dell S, Altincatal A, Gall R, Ledanois O, Sacks H, Jacob-Nara JA, Deniz Y, Rowe PJ

doi: 10.1002/ppul.27167

RECOMMENDED

Asthma

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

★ 1 Recommended by Dr Martin Frey, Faculty Member

Health Qual Life Outcomes

Meys R, Franssen FME, Van 't Hul AJ, Bakke PS, Caruso M, Dahlén B, Fowler SJ, Geiser T, Howarth PH, Horváth I, Krug N, Behndig AF, Singer F, Musial J, Shaw DE, Montuschi P, Zee AHM, Sterk PJ, Roberts G, Kermani NZ, Incalzi RA, Louis R, Andersson LI, Wagers SS, Dahlén SE, Chung KF, Adcock IM, Spruit MA, U-BIOPRED Study Group

doi: 10.1186/s12955-024-02321-3

COMMENTED

Asthma

The role of bronchial biopsy in the prediction of response to biological therapy in severe uncontrolled asthma: a prospective study

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Cosío BG, Iglesias A, Shafiek H, Mosteiro M, Escribano I, Toledo-Pons N, Valera JL, Bellvert CG, Pérez de Llano L

doi: 10.1016/j.chest.2024.11.045

Related content

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register

Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma

Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma

Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

The role of bronchial biopsy in the prediction of response to biological therapy in severe uncontrolled asthma: a prospective study